Our Company
BioMarin is a pharmaceutical company
that develops and provides innovative biopharmaceuticals
for rare diseases.
Corporate Philosophy
BioMarin is a global leader in developing biopharmaceuticals for rare diseases.
BioMarin is dedicated to patients facing rare diseases and their families.
Our mission is to deliver pharmaceuticals.
Some diseases are extremely rare, affecting as many as 1,000 people worldwide.
Such diseases are difficult to diagnose and
The reality is that treatment options are very limited.
BioMarin is also focusing on such diseases and exploring the possibility of drug development.
Our philosophy of putting patients first has remained unchanged since our founding.
Our Headquarters are located in San Raphael, California, USA.
Greeting from Our Representative
Rare Opportunities, Personal Impact
BioMarin Pharmaceutical Japan K.K., Ltd. is a small company.
Since Establishment in 2012, with a limited number of employees, we have continued to take on challenges with the mission of providing treatment options for rare diseases.
A rare disease, as the name suggests, means a disease with an extremely small number of patients.
Even in Japan, there are still many cases with limited or no effective treatment options.
We will continue to work together with patients, everyone who cares about them, healthcare professionals, and the general public to do what only we can do with all our might. We aim to bring you a smile.
As soon as possible, as many people as possible
We look forward to your continued support and guidance.
BioMarin Pharmaceutical Japan K.K.
Representative Director,
Kei Nakamura
BioMarin Pharmaceutical Japan K.K.
Representative Director Kei Nakamura
Corporate Information
BioMarin Pharmaceutical Japan K.K.
| Name | BioMarin Pharmaceutical Japan K.K. |
|---|---|
| Reading (in Japanese) | BioMarin Pharmaceutical Japan Kabushiki Kaisha |
| Company Location | JR Shinjuku Miraina Tower, 4-1-6 Shinjuku, Shinjuku-ku, Tokyo Click here for access |
| Telephone | 03-4578-0638 |
| Establishment | 2012/8/1 |
| Business Description | Our Science, manufacturing and sales of pharmaceuticals |
| Representative | Representative Director Kei Nakamura |
| No. of employees | 39 people (as of January 2024)  |
| Parent company | BioMarin Pharmaceutical Inc. |
Access
BioMarin Pharmaceutical Inc.
| Name | BioMarin Pharmaceutical Inc. |
|---|---|
| Headquarters Location | San Raphael, California, USA. |
| President & CEO | Alexander Hardy |
| No. of employees | About 3000 (worldwide) |
| Stock market listed | NSDAQ:BMRN |
| Sales volume | Approximately $1.85 billion (as of 2021) |
History
| 1997/3/1 | Established BioMarin Pharmaceutical Inc. (Headquarters in San Raphael, California, USA) |
|---|---|
| 2012/8/1 | BioMarin Pharmaceutical Japan K.K. was established in Toranomon, Tokyo. |
| 2013/8/1 | Acquisition of first-class drug manufacturing and sales license |
| 2014/12/1 | Obtained an approval for manufacturing and marketing a drug for mucopolysaccharidosis type IVA |
| 2015/4/1 | Started marketing of a drug for mucopolysaccharidosis type IVA |
| 2015/11/1 | Moved to Yoyogi, Shibuya-ku, Tokyo |
| 2019/3/1 | Transferred the approval to market a drug for mucopolysaccharidosis Type VI |
| 2019/9/1 | Obtained an approval for manufacturing and marketing a drug to treat neuronal ceroid lipofuscinosis |
| 2020/1/1 | Started marketing of a drug for neuronal ceroid lipofuscinosis type 2 |
| 2021/11/1 | Acquisition of pharmaceutical wholesale sales license |
| 2022/6/1 | Obtained manufacturing and marketing approval for Achondroplasia treatment drug |
| 2022/7/1 | Moved to the current address. |
| 2022/8/1 | Started marketing of a drug for Achondroplasia |
| 2023/3/1 | Obtained an approval for manufacturing a drug for Phenylketonuria treatment agent |
| 2023/5/1 | Started marketing of Phenylketonuria treatment agent |
Our Locations
Our Locations around the Globe
BioMarin has locations in the US, Europe, Japan, the Asia Pacific region, South America, and Middle East, to deliver drugs to patients around the globe.
